Hillisch Alexander, Pineda Luis Felipe, Hilgenfeld Rolf
Bayer HealthCare AG, Apratherweg 18a, D-42096 Wuppertal, Germany.
Drug Discov Today. 2004 Aug 1;9(15):659-69. doi: 10.1016/S1359-6446(04)03196-4.
Advances in bioinformatics and protein modeling algorithms, in addition to the enormous increase in experimental protein structure information, have aided in the generation of databases that comprise homology models of a significant portion of known genomic protein sequences. Currently, 3D structure information can be generated for up to 56% of all known proteins. However, there is considerable controversy concerning the real value of homology models for drug design. This review provides an overview of the latest developments in this area and includes selected examples of successful applications of the homology modeling technique to pharmaceutically relevant questions. In addition, the strengths and limitations of the application of homology models during all phases of the drug discovery process are discussed.
生物信息学和蛋白质建模算法的进展,以及实验性蛋白质结构信息的大量增加,有助于生成包含已知基因组蛋白质序列很大一部分同源模型的数据库。目前,对于所有已知蛋白质中的多达56%,可以生成三维结构信息。然而,关于同源模型在药物设计中的实际价值存在相当大的争议。本综述概述了该领域的最新进展,并列举了同源建模技术在药学相关问题上成功应用的实例。此外,还讨论了同源模型在药物发现过程各个阶段应用的优势和局限性。